AHMET ALTINTAŞ

Dr. AHMET ALTINTAŞ

İnternal medicine, Osmaniye Training and Research Hospital, Osmaniye, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAHMET ALTINTAŞ
AHMET ALTINTAŞ
MÖMehmet Turan Özer
Mehmet Turan Özer
ÖTÖmer Tepe
Ömer Tepe
ASAbdullah Sarıyıldırım
Abdullah Sarıyıldırım
Sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce cardiorenal events, but their association with insulin resistance in routine care is incompletely characterised, particularly where medication records cannot exclude exogenous insulin use. In this prospective, single-arm, single-centre cohort study, 54 adults with type 2 diabetes initiating an SGLT2 inhibitor were assessed at baseline, 3 and 6 months. Outcomes were HOMA-IR and the insulin-independent triglyceride–glucose (TyG) index within a family of 15 metabolic and laboratory variables, tested by Wilcoxon signed-rank test with Benjamini–Hochberg control and summarised as the rank-biserial correlation. Median HOMA-IR fell from 8.38 (IQR 3.47–13.26) to 3.14 (2.19–4.39), −62.6% (r = −0.79, adjusted p < 0.001), and the TyG index from 9.45 to 9.04 (−4.3%, r = −0.63, adjusted p < 0.001). Haemoglobin rose 5.0%, consistent with plasma-volume contraction. Change in HOMA-IR did not track change in HbA1c (ρ = −0.15, p = 0.27). An exploratory kidney-disease × time interaction was nominally significant for TyG (β = +0.31, p = 0.040) but not log-HOMA-IR (β = +0.39, p = 0.077). Because the design was single-arm and confounders unrecorded, these are associations observed during therapy, not treatment effects. The divergence between insulin-dependent and insulin-independent indices is relevant to endpoint selection in controlled studies.

1 January 2026 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
AAAHMET ALTINTAŞ
AHMET ALTINTAŞ
BABinhan Aslan Akbulut
Binhan Aslan Akbulut
TATUNAHAN ATES
TUNAHAN ATES
ESEmine Sukgen
Emine Sukgen
TSTayyibe Saler
Tayyibe Saler

6 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
İAİRFAN ALİŞAN
İRFAN ALİŞAN
AMAhmet Gazi Mustan
Ahmet Gazi Mustan
BIBektas Isik
Bektas Isik
FAFatih Necip Arıcı
Fatih Necip Arıcı
CDCahit Dinçer
Cahit Dinçer
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
Background: Diabetic retinopathy (DR) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a recognised marker of systemic vascular injury. Whether DR—graded independently by two experienced ophthalmologists as part of routine institutional care—is independently associated with concurrent nephropathy (urine albumin-to-creatinine ratio [UACR] ≥ 30 mg/g) and subclinical cardiac stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥ 125 pg/mL) remains insufficiently examined. Methods: Retrospective cross-sectional study of 401 T2DM adults who underwent dilated fundus examination independently graded by two board-certified ophthalmologists (each ≥ 10 years’ experience in diabetic eye disease) using ETDRS-based classification. Inter-physician agreement was quantified by Cohen’s weighted kappa. The primary composite outcome was concurrent nephropathy and subclinical cardiac stress. Multivariable logistic regression adjusted for age, sex, HbA1c, diabetes duration, eGFR, hypertension, and pharmacological treatments. Results: The composite outcome was present in 120 (64.2%) DR-positive vs. 14 (6.5%) DR-negative patients (crude OR: 25.59 (13.78–47.51); p < 0.001; fully adjusted OR: 21.49 (11.02–41.81); p < 0.001). Inter-physician agreement was high (Cohen’s weighted κ = 0.88; 95% CI: 0.83–0.93). Nephropathy alone was found in 164 (87.7%) vs. 76 (35.5%) patients (OR: 12.95 (7.71–21.75); p < 0.001), and elevated NT-proBNP in 137 (73.3%) vs. 39 (18.2%) patients (OR: 12.29 (7.65–19.76); p < 0.001). A significant trend across DR severity grades was observed (p for trend < 0.001), although the gradient was not strictly monotonic. ROC AUC = 0.837 (95% CI: 0.784–0.860). Conclusions: Ophthalmologist-graded DR was independently associated with the concurrent presence of albuminuria and elevated NT-proBNP in T2DM. Because the design is cross-sectional, these findings describe association rather than prediction or causation. They generate the hypothesis that retinal grading may help flag patients in whom cardiorenal biomarker assessment is worth considering, but prospective validation is required before any screening application.

16 October 2026 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
BABinhan Aslan Akbulut
Binhan Aslan Akbulut
AAAHMET ALTINTAŞ
AHMET ALTINTAŞ
ESEmine Alyamaç Sukgen
Emine Alyamaç Sukgen
TSTayyibe Saler
Tayyibe Saler
LELina Elmas
Lina Elmas

Verified
Journal Article
Open access
PDF file
AAAHMET ALTINTAŞ
AHMET ALTINTAŞ
MÖMehmet Turan Özer
Mehmet Turan Özer
ÖTÖmer Tepe
Ömer Tepe
ASAbdullah Sariyildirim
Abdullah Sariyildirim
Background/Objectives: Glucose-lowering treatment can change insulin resistance indices without demonstrating improved insulin sensitivity. We described these changes during sodium–glucose cotransporter-2 (SGLT2) inhibitor therapy in routine care. Methods: In this prospective, uncontrolled observational cohort, 54 adults with type 2 diabetes were assessed at baseline, 3 and 6 months. Background medication was abstracted from hospital and prescription records. Exploratory baseline-to-6-month comparisons used Wilcoxon signed-rank tests with Benjamini–Hochberg adjustment across 15 analysed outcomes. Results: Median HOMA-IR decreased from 8.38 (IQR 3.47–13.26) to 3.14 (2.19–4.39), a 62.6% reduction in group medians (rank-biserial r = −0.79; adjusted p < 0.001); in the 41 participants without documented insulin use, the reduction was 50.9% (r = −0.76). Median triglyceride–glucose (TyG) index decreased from 9.45 to 9.04 (−4.3%; r = −0.63; adjusted p < 0.001). Change in HOMA-IR was not significantly correlated with change in HbA1c (ρ = −0.15; p = 0.27). Conclusions: Both indices decreased during follow-up, including in participants without documented insulin use, but these observations cannot establish a treatment effect or improved insulin sensitivity. TyG requires no insulin measurement but remains sensitive to glucose- and triglyceride-lowering therapies, including SGLT2 inhibitors. Controlled studies with direct measures of insulin sensitivity are needed.